Compare BNZI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | KPRX |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 9.2M |
| IPO Year | N/A | N/A |
| Metric | BNZI | KPRX |
|---|---|---|
| Price | $1.23 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.00 | $10.00 |
| AVG Volume (30 Days) | ★ 537.6K | 51.8K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,650,176.00 | N/A |
| Revenue This Year | $223.24 | N/A |
| Revenue Next Year | $31.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.06 | N/A |
| 52 Week Low | $1.09 | $1.77 |
| 52 Week High | $27.00 | $4.18 |
| Indicator | BNZI | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 47.60 |
| Support Level | $1.14 | $2.00 |
| Resistance Level | $1.40 | $2.17 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 31.83 | 77.81 |
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.